Royal jelly’s anti-inflammatory and immunomodulatory activities are suitable in treating atopic dermatitis, hyperkeratosis, epidermis and dermis inflammation, or hypertrophy, most probably via a combination of TNF-specific low adjustment of IFN-gamma unique secretion and excessive adjustment of nitric-oxide synthase expression. The gene discussed is TNF; the disease is atopic eczema.